Pathway-Guided and Patient-Centered Therapeutic Strategies in Atherosclerotic Cardiovascular Disease

Clicks: 55
ID: 331821
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #50 of 288 articles by views in european journal of preventive cardiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 288 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Atherosclerotic cardiovascular disease (ASCVD), encompassing coronary artery disease (CAD), cerebrovascular disease (ischemic stroke, IS; and transient ischemic attack, TIA), and peripheral artery disease (PAD) of atherosclerotic origin, remains a leading cause of morbidity and mortality worldwide despite major advances in prevention and treatment. Although atherosclerosis arises from the convergence of endothelial injury, lipid accumulation, inflammation, and thrombosis, the relative contribution of these pathogenic processes varies markedly among individuals, due to the effects of genetics, demographic, and racial factors, lifestyle behaviors and comorbidities, several of which are modifiable. The variability in the atherosclerosis underlying mechanisms results in substantial heterogeneity in clinical presentation, disease progression, and therapeutic response. Recently, ASCVD management has expanded beyond single-pathway intensification toward pathway-guided, patient-centered, multi-targeted therapeutic strategies. Over the past decade, we have witnessed the development of highly specific therapeutics, including small-molecule inhibitors, monoclonal antibodies, and RNA-based therapies, while genome-editing approaches remain at an investigational stage. Contemporary Phase 3 randomized controlled trials (RCTs) have demonstrated that several novel agents reduce cardiovascular (CV) risk, whereas others produce biological effects without improving outcomes, underscoring the need for outcome-based validation. Despite improved safety profiles and enhanced treatment adherence, the optimal integration of these therapies into clinical practice continues to evolve. In this narrative review, we evaluate evidence from established, emerging, and investigational therapeutic strategies for ASCVD prevention and treatment. We also describe the impact of endothelial-protective, lipid-lowering, anti-inflammatory, and antithrombotic, strategies on CV outcomes, with particular emphasis on differential efficacy across patient subgroups, vascular territories, and clinical settings. In addition to synthesizing evidence from contemporary clinical trials, this review proposes a novel pathway- and phenotype-based conceptual framework for individualized ASCVD management and secondary prevention. The framework integrates residual-risk phenotypes with clinical characteristics, comorbidities, vascular territory, and treatment-related considerations to support residual-risk-guided selection of complementary evidence-based therapies while balancing anticipated benefit, safety, treatment burden, and adherence.
Reference Key
openalex_W7220932552 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Mario Enrico Canonico, Marisa Avvedimento, Felice Borrelli, Giuseppe Giugliano, Giuseppe Gargiulo, Raffaele Piccolo, Eugenio Stabile, Luisa Mestroni, Matthew R.G. Taylor, Suet N. Chen, Giovanni Esposito, Marc P. Bonaca, Raffaella Lombardi
Are you one of these authors? Claim your profile
Journal european journal of preventive cardiology
Year 2026
DOI
10.1093/eurjpc/zwag523
URL
https://doi.org/10.1093/eurjpc/zwag523
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.